[1] |
Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: beyond reverse cholesterol transport[J]. Curr Drug Targets, 2008, 9(3):196-203.
|
[2] |
Besler C, Heinrich K, Riwanto M, et al. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease[J]. Curr Pharm Des, 2010, 16(13):1480-1493.
|
[3] |
Sun HY, Shen D, Zhang CH, et al. Meta-analysis on the correlation between APOM rs805296 polymorphism and risk of coronary artery disease[J]. Med Sci Monit, 2016(22):8-13.
|
[4] |
Christensen PM, Liu CH, Swendeman SL, et al. Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1[J]. FASEB J, 2016, 30(6):2351-2359.
|
[5] |
Ruiz M, Okada H, Dahlbäck B. HDL-associated apoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium[J]. Lipids Health Dis, 2017(16):36.
|
[6] |
Arkensteijn BWC, Berbée JFP, Rensen PCN, et al. The apolipoprotein m-sphingosine-1-phosphate axis: biological relevance in lipoprotein metabolism, lipid disorders and atherosclerosis[J]. Int J Mol Sci, 2013, 14(3):4419-4431.
|
[7] |
Potì F, Simoni M, Nofer JR. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)[J]. Cardiovasc Res, 2014, 103(3):395-404.
|
[8] |
Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M[J]. Proc Natl Acad Sci U S A, 2011, 108(23):9613-9618.
|
[9] |
Sutter I, Park R, Othman A, et al. Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate[J]. J Lipid Res, 2014, 55(8):1730-1737.
|
[10] |
梁云,罗光华,刘宏, 等. 人脐静脉内皮细胞1-磷酸鞘氨醇受体鉴定及其应用探讨[J]. 天津医药, 2016, 44(6):662-664.
|
[11] |
石小岩,廖爱军. 1-磷酸鞘氨醇受体的研究进展[J]. 实用药物与临床, 2016, 19(4):506-509.
|
[12] |
Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for preβ-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis[J]. Nat Med, 2005, 11(4):418-422.
|
[13] |
Xu N, Zhang XY, Dong X, et al. Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells[J]. Biochem Biophys Res Commun, 2002, 292(4):944-950.
|
[14] |
Gao JJ, Hu YW, Wang YC, et al. ApoM suppresses TNF-a-induced expression of ICAM-1 and VCAM-1 through inhibiting the activity of NF-kB[J]. DNA Cell Biol, 2015, 34(8):550-556.
|
[15] |
De Palma C, Meacci E, Perrotta C, et al. Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium[J]. Arterioscler Thromb Vasc Biol, 2006, 26(1):99-105.
|
[16] |
Nofer JR, Van Der Giet M, Tölle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3[J]. J Clin Invest, 2004, 113(4):569-581.
|